-
Something wrong with this record ?
CIP/KIP and INK4 families as hostages of oncogenic signaling
L. Csergeová, D. Krbušek, R. Janoštiak
Status not-indexed Language English Country England, Great Britain
Document type Journal Article, Review
Grant support
PRIMUS/22/MED/007
Univerzita Karlova v Praze
National Institute for Cancer Research #LX22NPO5102
European Union - Next Generation EU, Programme EXCELES
NLK
BioMedCentral
from 2006-12-01
BioMedCentral Open Access
from 2006
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
Springer Nature OA/Free Journals
from 2006-12-01
- Publication type
- Journal Article MeSH
- Review MeSH
CIP/KIP and INK4 families of Cyclin-dependent kinase inhibitors (CKIs) are well-established cell cycle regulatory proteins whose canonical function is binding to Cyclin-CDK complexes and altering their function. Initial experiments showed that these proteins negatively regulate cell cycle progression and thus are tumor suppressors in the context of molecular oncology. However, expanded research into the functions of these proteins showed that most of them have non-canonical functions, both cell cycle-dependent and independent, and can even act as tumor enhancers depending on their posttranslational modifications, subcellular localization, and cell state context. This review aims to provide an overview of canonical as well as non-canonical functions of CIP/KIP and INK4 families of CKIs, discuss the potential avenues to promote their tumor suppressor functions instead of tumor enhancing ones, and how they could be utilized to design improved treatment regimens for cancer patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013092
- 003
- CZ-PrNML
- 005
- 20240726151522.0
- 007
- ta
- 008
- 240723s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13008-024-00115-z $2 doi
- 035 __
- $a (PubMed)38561743
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Csergeová, Lucia $u BIOCEV-First Faculty of Medicine, Charles University, Prague, Czechia
- 245 10
- $a CIP/KIP and INK4 families as hostages of oncogenic signaling / $c L. Csergeová, D. Krbušek, R. Janoštiak
- 520 9_
- $a CIP/KIP and INK4 families of Cyclin-dependent kinase inhibitors (CKIs) are well-established cell cycle regulatory proteins whose canonical function is binding to Cyclin-CDK complexes and altering their function. Initial experiments showed that these proteins negatively regulate cell cycle progression and thus are tumor suppressors in the context of molecular oncology. However, expanded research into the functions of these proteins showed that most of them have non-canonical functions, both cell cycle-dependent and independent, and can even act as tumor enhancers depending on their posttranslational modifications, subcellular localization, and cell state context. This review aims to provide an overview of canonical as well as non-canonical functions of CIP/KIP and INK4 families of CKIs, discuss the potential avenues to promote their tumor suppressor functions instead of tumor enhancing ones, and how they could be utilized to design improved treatment regimens for cancer patients.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Krbušek, David $u BIOCEV-First Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Janoštiak, Radoslav $u BIOCEV-First Faculty of Medicine, Charles University, Prague, Czechia. radoslav.janostiak@lf1.cuni.cz
- 773 0_
- $w MED00173234 $t Cell division $x 1747-1028 $g Roč. 19, č. 1 (2024), s. 11
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38561743 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151515 $b ABA008
- 999 __
- $a ok $b bmc $g 2125599 $s 1224955
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 19 $c 1 $d 11 $e 20240401 $i 1747-1028 $m Cell division $n Cell Div $x MED00173234
- GRA __
- $a PRIMUS/22/MED/007 $p Univerzita Karlova v Praze
- GRA __
- $a National Institute for Cancer Research #LX22NPO5102 $p European Union - Next Generation EU, Programme EXCELES
- LZP __
- $a Pubmed-20240723